Page 7 - Dane Leone News Today

Operator Good day, and thank you for standing by. Welcome to the Galapagos Financial Results Q1 2021 Conference Call. [Operator Instructions] Please be advised that todays conference is being recorded. [Operator Instructions] I would now like to hand the conference over to your first speaker today, Elizabeth Goodwin. Please go ahead. Elizabeth Goodwin -- Vice President of Investor Relations Thank you all, and welcome to our call today. Im Elizabeth Goodwin, Investor Relations, and the webcast ...

Markets After Needham and H.C. Wainwright gave G1 Therapeutics (NASDAQ: GTHX) a Buy rating last month, the company received another Buy, this time from Raymond James. Analyst Dane Leone maintained a Buy rating on G1 Therapeutics today. The company’s shares closed last Wednesday at $22.63. According to TipRanks.com, Leone is a 5-star analyst with an average return of 15.6% and a 62.7% success rate. Leone covers the Healthcare sector, focusing on stocks such as Adverum Biotechnologies, Tarsus ...

Amgen Inc (AMGN) Q1 2021 Earnings Call Transcript Motley Fool Transcribers © The Motley Fool Logo of jester cap with thought bubble. Amgen Inc (NASDAQ: AMGN) Operator My name is Erica, and I will be your conference facilitator today for Amgens First Quarter 2021 Financial Results Conference Call. [Operator Instructions] I would now like to introduce Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may now begin.SPONSORED: 10 stocks we like better than Amgen...

Markets Bristol Myers (BMY) Raymond James analyst Dane Leone maintained a Buy rating on Bristol Myers today. The company’s shares closed last Friday at $66.01, close to its 52-week high of $67.16. According to TipRanks.com, Leone is a 5-star analyst with an average return of 15.3% and a 62.7% success rate. Leone covers the Healthcare sector, focusing on stocks such as Adverum Biotechnologies, Tarsus Pharmaceuticals, and Allogene Therapeutics. Bristol Myers has an analyst consensus of Strong ...

Cytokinetics Inc (CYTK) Q4 2020 Earnings Call Transcript Motley Fool Transcribers © The Motley Fool Logo of jester cap with thought bubble. Cytokinetics Inc (NASDAQ: CYTK) Operator Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics Fourth Quarter 2020 Conference Call. [Operator Instructions] I will now turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Creations and Investor Relations. Please go ahead. This article is a transc...

Order Reprints Text size JAK inhibitors such as filgotinib block enzymes that cause much of the mischief in autoimmune diseases. Dreamstime Gilead Sciences plunked down $5 billion last year to partner with Belgium’s Galapagos on treatments for autoimmune disorders such as arthritis and Crohn’s disease. Galapagos’s lead drug candidate was filgotinib, a so-called JAK inhibitor undergoing clinical trials in the U.S. and Europe. But in August of this yea...